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ABSTRACT
USE OF ALUMINO-CALCIUM-PHOSPHOROUS-OXIDE 
(ALCAP) CERAMIC CAPSULES
FOR DELIVERING
POLYPEPTIDES OF VARIOUS MOLECULAR WEIGHTS
Ateegh A. K. Al-Arabi 
University of Dayton
Major Professor: P. K. Bajpai, Ph. D.
Ceramics composed of metallic oxides of calcium, phosphorous,
aluminum and silicon in various combinations are biocompatible andhave
been used as prosthetics in animals as well as humans. Preliminary
studies conducted by Khot, et al. (1980) established that ALCAP ceramics
were capable of delivering insulin in a static system. The purpose of
this investigation was to study the capability of ALCAP ceramics to de­
liver gamma globulin (M. W. 150,000), bovine serum albumin (M.W.
69, 000) chymotrypsinogen (M.W. 26,000) and insulin (M.W. 5, 766) in 
an in vitro continuous flow system over a period of seven days at 37°C.
Hollow ALCAP ceramic cylinders 2 cm long having outside and
inside diameters of 1.3 and 0.5 cm respectively were fabricated from
three different size (35-45, 45-60, and 60-75 um) calcined particles.
Each ceramic capsule was sintered at 1425°C for 24 hours. The open 
ends of each ceramic capsule were sealed with a silicone rubber seal­
ant. A 0. 5 ml polypeptide solution having a concentration of 100 mg
per ml was injected into each capsule by means of an 18 gauge needle.
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The punctured end of the capsule was resealed to ensure the release
of polypeptides through the ceramic pores.
Ceramics containing the polypeptides were placed in a continu­
ous flow-through system chamber and a current of 0. 2 ml per minute
of phosphate buffered saline (pH 7.4) was perfused through the chamber 
at 37°C. The effluent was collected every 24 hours for seven days and 
the concentration of protein in the effluent was determined by the pro­
cedure of Lowry, et al. (1951). The entire investigation was conducted
using triplicates of ceramics and aliquots. All the data collected were
analyzed by means of analysis of variance at P<.. 05.
The release pattern of the four different substances was signi­
ficantly influenced by the particle size of the ceramic capsules, the
molecular weight of the polypeptide and the passage of time. None of
the above parameters had a significant effect on the pH of the phosphate
buffered saline effluent.
The ceramics studied are capable of delivering polypeptides of
various molecular weights and can be used effectively as depots for de­
livering polypeptides in vivo.
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INTRODUCTION
Procedures for controlling the release of compounds have been
recognized for many years. The concept of controlled release of chemi­
cals was first used in the agricultural industry. To date farmers have
reaped the benefit of releasing fertilizers slowly for more than thirty- 
five years. In the pharmaceutical field prolonged release of oral medi­
cations have been achieved by various techniques for more than thirty
years.
The goal of the pharmaceutical industry is to achieve a minimum
rate of drug delivery with maximum effects. This objective has been
achieved to a certain extent with controlled release of certain kinds of
drugs. However, delivery of polypeptide products cannot be achieved
by these procedures since the enveloping procedure often requires chemi
cal and thermal treatments.
Rejection of tissues capable of producing hormones has also been
an insurmountable problem. However, attempts to reduce the immune
response and increase the acceptance of such tissues are in progress.
A motorized portable insulin-delivery pump has been developed
and used successfully in insulin-dependent dogs. This device is also 
undergoing clinical trials in some laboratories. Several implantable,
miniaturized, self-contained, and self-powered osmotic pumps have
1
2also been developed. However, the approval of latter device for human
use is remote since they cannot be refilled in situ and will have to be
recovered and replaced. The latter would naturally require repeated
operative procedures and thus seems impractical.
Ceramics have been widely used for orthopaedic and dental im­
plantation. The possibility of using aluminum based ceramic material
as a means of controlled drug delivery system was recently advocated
by Khot et al, (1980).
Molecular weights of different hormones and drugs vary widely.
Therefore, whenever one thinks about developing a procedure for hor­
mone or drug delivery, one should take into account both the needs of
the patient and the characteristics of the needed hormone or drug.
This present investigation was designed to study the ability of
the alumino-calcium-phosphorous oxide (ALCAP) ceramics to deliver
gamma globulin (150, 000 Daltons), bovine serum albumin (69, 000 Dal­
tons), chymotrypsinogen-A (26,000 Daltons) and insulin (5,766 Daltons)
in a continuous flow-through system of phosphate buffered saline (pH 7.4)
at 37°C. The main objective of these experiments was to show the gen­
eral profile of delivery of each of these four polypeptides and also the
range of molecular weight that can be delivered by ALCAP ceramics.
REVIEW OF LITERATURE
Controlled Drug Delivery
Man has yet to perfect drug delivery devices which can regulate
the blood glucose levels of diabetics. According to Cahill, et al. (1976) 
and Ingelfinge r (1977) there is a strong relationship between the regula­
tion of blood glucose and the development of long-term microangiopathic
and neuropathic complications in diabetes mellitus. Even under optimal
conditions, conventional treatment with insulin is associated with wide
swings in plasma glucose well outside the normal range (Service, et al.
1970). Treatment of juvenile-onset diabetes with multiple injections of
rapid-acting or intermediate-acting insulin are associated with persis­
tence of hyperglycemia (plasma glucose in excess of 200 mg %) or the 
development of hypoglycemia (plasma glucose less than 50 mg %) or both
(Service, et al. 1970, and Molnar, et al. 1972). In contrast the plasma
glucose concentration in healthy subjects on their usual diet, generally 
does not vary more than 40-60 mg % and remains between 70-120 mg %
when monitored over a duration of 24 hours (Service, et al. 1970, and
Tasaka, et al. 1975).
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4Implantable Delivery Devices
The blood glucose regulation was markedly improved for a period
of 12 to 24 hours with the use of an artificial pancreas (Albisser, et al.
1974, and Mirouze, et al. 1977). This device provided the maintenance
of the blood glucose concentration within a desired range by the continu­
ous intravenous infusion of insulin at a variable rate. Regulation of the
insulin-infusion rate on a moment-to-moment basis was established
by on-line monitoring of the blood glucose and computerized feedback
signal (Albisser, et al. 1974). However the use of such a device is limit­
ed by the lack of an implantable glucose sensor and the need for continu­
ous blood withdrawal and the attachment of the patient to a glucose analy­
zer. Genuth, et al. (1977 ) and Service (1978) reported an improved blood
glucose regulation without feedback control of insulin-delivery rates by
increasing the amount of insulin delivery before each meal. However,
infection and thrombosis are always inherent with the use of any long­
term intravenous delivery system (Tamborlane, et al. 1979).
Pickup, et al. (1978) employed a pre-programmed insulin-deli­
very system in which insulin was administrated via the subcutaneous
route by means of a portable infusion pump. However this device can
deliver insulin only on a fixed basis (8X of the basal rate). Reduction
in mean blood glucose concentration was achieved in only six of fourteen
patients by the use of this device and two patients exhibited serious
problems in regulating blood levels of glucose (Pickup, et al. 1978).
Recently Tamborlane, et al. (1979) have used a subcutaneous portable,
battery-powered infusion system to deliver insulin. By means of this
device they were able to adjust delivery of insulin at different pre-meal
insulin and basal infusion rates. While most of the pre-programmed
insulin-delivery systems have been studied in adult subjects (Genuth,
et al. 1977 and Pickup, et al. 1978) the delivery of insulin by Tambor­
lane, et al. 's (1979) device was studied in children and adolescents.
The regulation of blood glucose level in this age group has always beena
difficult tas k and is associated with higher risks of long-term microvas-
cular complications (Cahill, et al. 1976). Since the drug is delivered
by means of a 27-gauge needle inserted in the subcutaneous tissue the
toxic effects of metal corrosion cannot be ignored. The device cannot
be used by everyone since the patient has to be educated to use the com­
puter-controlled delivery system. Since insulin is destroyed selective­
ly in subcutaneous tissue (Duckworth and Kitabchi, 1981), the system
will also need constant upgrading to overcome the increase in enzyme
activity. However at present the future of this device looks quite good
for a select group of individuals.
Osmotic Pump Delivery Systems
Alza Corporation (Palo Alto, California, 94303) has developed 
small self-powered, continuous-delivery infusion pumps of different
6kinds for in vivo or in vitro use in the laboratory. These pumps also
do not require external connections (Yates, 1978). According to Ecken­
hoff, et al. (1976) an osmotic minipump (Alzet Osmotic Minipump) is a 
cylinderical device (25 mm in length and 6. 5 mm in diameter) for fluid
release which can be implanted subcutaneously or interaperitoneally in
animals as small as the mouse, for parenteral administration of bioactive
agents at constant rates for periods up to 7 days. The external surface
of the minipump is composed of a rate-controlling semi-permeable mem­
brane. The inside deformable drug reservoir is coated with an osmotic
agent. Since the semipermeable membrane is made of cellulose it is
biocompatible. When a minipump is placed within a living animal, water
is pulled osmotically into the reservoir by the osmotic agent at a rate con
trolled by the membrane. Since the membrane is rigid, the entrance of
water displaces the material from the reservoir, which collapses gradu­
ally with time, pumping the contents out of the minipump. The 170 micro
liter reservoir is filled by the user. The reservoir is compatible with
water, physiogical salt solutions, polyethylene glycols, propylene glycol,
and with dilute aqueous ethanol. The duration of delivery depends on the
type of membrane. This implanted minipump can also be connected to
a small catheter for systemic delivery or administration of agents intra­
venously, intra cisternally, or tissue sites.
7The use of Alzet osmotic minipump in laboratory research
started in the early 1977. The minipump was mainly designed for
use in small laboratory animals, but by simultaneously implanting
multiple pumps an investigator may achieve adequate mass fluxes in
dogs, monkeys, baboons, sheep, goats, or other large animals. For
example normal blood sugar levels have been successfully maintained
in a severely diabetic dogs weighing 33 kilograms, by means of four
minipumps each delivering 0.25 U of insulin per hour subcutaneously
(Yates, 1979).
Minipumps have usually been implanted subcutaneously and less
commonly intraperitoneally. Infusion of tissues has also been attained
with the aid of a minipump fitted with a catheter flow moderator. Infu­
sion of various fluids and drugs in the ventricular system of the brain,
lumen of the uterus, fornix of the eye, corneal tissue, venous system,
tissue of the visual cortex, and cerebspinal fluid system have been
achieved by the use of the minipumps fitted with catheters (Benson, 1979)
Siew and Goldstein (1976)used the Alzet Osmotic Minipump to adminis­
ter sodium barbital to mice at a constant rate of about 0. 5 mg per hour
for studying the possibility of rapid development of barbiturate tolerance
and physical dependence. They concluded that the osmotic pumps may
be useful in studying the mechanisms of barbiturate tolerance and depen­
dence.
8Alzet Osmotic Minipumps have also been used to study the ef­
fects of prolonged continuous low rate delivery of antigen on primary
and secondary immune responses (Amkraut, et al. 1976). Martins,
and Amkraut (1978) immunized mice with tetanus toxoid antigen mixed
with graded doses of li popolysaccharides using an osmotic minipump
and subcutaneously by means of single injection of the mixture. Results
of their study showed that tetanus toxoid in same doses was significantly
more immunogenic when delivered continuously by means of a minipump. 
The data obtained by these workers are important in the sense thatthey show
effective utilization of the pump in immunizing animals. However, it
also points out the fact that the same phenomenon can occur when some
other biological agents capable of eliciting an immune response are ad­
ministered by means of an osmotic pump.
Osmotic minipumps have also been used for infusing thyrotropin­
releasing hormone (TRH) over a period of five days. These studies were
conducted to investigate the effects of TRH on secretation of prolactin
and growth hormone from the pituitary. The experiment was conducted
in ovariectomized ewes and the minipumps implanted subcutaneously suc­
ceeded in providing a sustained release of 500 ug of hormone per day
(Klindt, et al. , 1979).
An osmotic minipump filled with 170 ul of an aqueous sodium pork
insulin solution of 3200 U/ml in 1.6% glycertol (pH 7.4) has also been
placed in a subcutaneous tunnel in the posterior aspect of the upper leg
9of rhesus monkey fetus. In this position the minipump was reported
to deliver 19 U or 6 ul of insulin per day continuously for 28 days
(Susa, et al. 1979).
McDonald, et al. (1980) used the Alzet osmotic minipump to deliver
a test solution to the brain of rats by means of PE 60 tubing connected
to the minipump cannula. The osmotic pump was inserted between the
two scapulas. The test solution by this technique can be delivered at 
a constant rate of 1 ul/h +. 15% (Wei and Loh, 1976). Continuous infu­
sion of angiotensin II at the rate of 50 ng/min has been attained by im­
planting the osmotic minipump in rats. This implantationprocedure has
been employed to study the effects of increased levels of circulating
angiotensin II upon the steroidogenic activity of the adrenal glomerulosa
cells. Prolonged infusion of angiotensin II in normal and hypophysec-
tomized rats was found to reduce the effects of sodium restriction on
angiotensin II receptors and enzymes of the aldosterone biosynthetic
pathway (Aguilera, et al. , 1980).
After dissolving a converting enzyme inhibitor (SQ 14,225) of
angiotensin I to angiotensin II in phosphate buffered saline containing
0.5 mM ascorbic acid, Schirar, et al. (1980) administered the solu­
tion by means of an intraperitoneally implanted osmotic minipump at 
the rate of 1 ug/min in pregnant rats. Angiotensin II concentrations 
did not change between day 4 and 9 of pregnancy in the sterile horns 
and indicated that the plasma angiotensin II levels did not play a role
in the non-gravid uterine horns.
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Harwood, et al. (1980) implanted Alzet osmotic minipumps in
the peritoneal cavities of female gonadotropin-primed rats to infuse
gonadotropin-releasing hormone (GnRH) agonist analogs in order to
determine whether the immature ovary contained gonadotropin-releas­
ing hormone receptors before gonadotropin priming, Theyalso wanted
to know whether gonadotropin-releasing hormone was capable of anto-
gonizing the effect of exogenous pregnant mare serum gonadotropin
(PMSG) and human chorionic gonadotropin (HCG) during the maturation
process of the ovaries. Results of their investigation showed that the
administration of GnRH agonist analogs completely inhibited the trophic
actions of both gonadotropins. The GnRH induced a decreas e in luteinizin
hormone (LH) and prolactin (PRL) receptors in hypophysectomized ani­
mals indicating that GnRH agonist analogs can act directly on the ovary
and that their effects are not only due to the secondary release of gonado
tropins from the pituitary gland.
Mode, et al. (1981) used Alzet osmotic minipumps for continu­
ous administration of human growth hormone (hGH) at the rate of 5 ug/h
for seven days in normal male rats under varying conditions to study 
14the metabolism of 4-(4- C) androstene -3-17-dione in the microsomal
fraction of rat livers. They also used the pumps for continuous infusion
of prolactin and growth hormone to study the effects of these homolo­
gous hormones on the hepatic steroid metabolism. Both hormones
were infused continuously at the rate of 10 ug/h for
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seven days, to increase the serum concentrations of the hormones to
normal levels in hypophysectomized animals. Human growth hormone 
was found to cause a complete feminization of the hepatic steroid meta­
bolism (i. e. , it increased the 5°< - reductase and decreased the 6 A 
and 16- - hydroxylase activities). The feminizing capacity of the
human growth hormone was affected neither by hypophysectomy and
castration nor by adrenalectomy and thyroidectomy of male rats,
indicating that the adrenal and thyroid gland are not involved in the
mediation of the feminizing effect of the human growth hormone. The
same dose of human growth hormone also refeminized the liver steroid
metabolism in hypophysectomized-ovariectomized female rats. Rat
growth hormone caused a partial feminization of the hepatic steroid
metabolism in hypophysectomized male animals, rat-PRL did not cause
feminization of these rats. The results of these studies show that growth
hormone or growth hormone related hormones are involved in sexual
differentiation of liver steroid metabolism (Mode, et al. 1981).
The administration of ovine-PRL or bovine growth hormone as
well as a combination of both hormones by means of an Alzet osmotic
minipump has been reported by Norsted, et al. (1981). According to
them administration of growth hormone by these procedures induces
the development of estrogen receptors in the livers of dexamethasone-
treated hypophysectomized rats. However complete restoration of hepa­
tic estrogen receptor levels was not achieved by administration of rat- 
PRL by osmotic minipumps (Norsted, et al. 1981).
12
Polymer Delivery Systems
Hormonal contraceptive therapy requires that the drug be ad­
ministered orally or intramuscularly. These two methods usually
have certain disadvantages. The daily intake of the tablets in the oral
method can result in harmful side effects, such as cancer. Although
the intramuscular administration of the contraceptive drugs (steroids)
prevents conception for extended periods it cannot be reversed quickly
(Roseman, 1974).
In order to overcome the side effects usually associated with the
oral administration of contraceptive steroids, a biodegradable drug de­
livery system was developed by Sidman, et al. (1976). They encap­
sulated steroids in glutamic acid and leucine co-polymers. The ob­
jective of this work was to fabricate an injectable biodegradable drug
reservoir that would provide a constant, controlled drug release of
contraceptives for 6 to 12 months. In one of the two approaches used
in this study approximately 40 to 60% progesterone was dispersed in
a sintered network structure of the polymer. After providing an initial
peak of progesterone the rod-shaped capsular implants released the
hormone in a consistent manner for more than 100 days in rats. Rods
of smaller size showed a more consistent progesterone release pattern
than rods of larger dimensions. Rate of progesterone release after 
the initial peak dropped significantly on implantation of larger size
rods.
13
Pitt, et al. (1976) characterized homo and copolymers of
glycoside, DL-Lactide, E-caprolactone, DL-E-decalactone and other
monomeric and dimeric lactones for developing a new biodegradable
polymer subdermal steroid release system. They reported that the
biodegradation of films and capsules of these polymers was not depen­
dent on the chemical structure but rather on the molecular weight and
morphology of the polymer.
Nuwayser, et al. (1976) developed a procedure for microencap
sulating progesterone in a bioresorbable homopolymer of L(-) lactide.
According to them the microcapsules when injected in a suspension
phase should be absorbed by the host after the completion of drug de­
livery. The goal of these investigations was to provide semipermeable
capsule reservoirs for delivering progesterone at a constant rate for
a period of one year. The microencapsulation was done either by the
process of coocervation, coagulation or air suspension coating. Injec
tion of progesterone, encapsulated by the above procedure, in rabbits
resulted in an initial rapid delivery of the hormone and was followed
by a sustained release of the hormone for about 90 days.
Prostaglandins have been used in the third trimester to ter­
minate pregnancies. However large doses of prostaglandin-F (PGF2)
have serious side effects. Hence Davis and Chang (1972) studied the
feasibility of administering PGF2 by means of polyacrylamide and
silastic tubes.
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According to Davis and Chang (1972) polyacrylamide polymer 
allowed better delivery of PGF2 in the surrounding media when tested
in an in-vitro testing system. They also reported a significant decrease
in pregnancy on implanation of the PGF2 polyacrylamide reservoirs in
the vagina of hamsters two days after mating. Remating of these ham­
sters after the withdrawal of the PGF2 polyacrylamide reservoirs re­
sulted in restoration of the fertility and pregnancy.
Davis (1974) also observed absorption of various radioactively
labelled substances from cylindrical polyacrylamide and polyvinylpy-
rolidone implants. They observed the release of bovine serum albumin,
rabbit immunoglobulin, bovine pancreatic insulin and rat luteinizing
hormone, Nax I and (3H) prostaglandin F2 (PGF2) from the polyacry­
lamide and polyvinylamide reservoirs. The absorption rate of each of
the above solutes (in vivo) was used to determine its diffusion coeffici­
ent. The diffusion coefficient of the enclosed material showed a logari­
thmic relationship between the concentration of the cross-linked poly­
mer gels and the molecular weight of each solute. The in vivo relation­
ship between the delivery rate of the substance and the polymer was
later confirmed by in-vitro studies.
Silicone Rubber Delivery Systems 
In the last two decades contraceptive steroids have been delivered
by means of silicone rubber (polydimethylsiloxane) devices (Roseman, 1974)
15
The importance of implantation of drugs in capsules of silastic 
(polydimethylsiloxane) and their prolonged local or systemic adminis­
tration was realized first in 1964 by Folkman and Long. A wide range
of application including use in experimental medicine, treatment of
chronic diseases, prophylaxis of infectious diseases or allergies was 
advocated by Folkman and Long (1964).
The most significant application of silicone rubber involved the
diffusion of anesthetic and analgesic drugs (Folkman, et al. , 1966). 
Folkman and Mark (1968) were able to induce anesthesia and analgesia
in dogs by passing the vapors of either nitrous oxide, ether, halothane,
or cyclopropane, through a coil of silicone rubber tubing, each end of
which was placed in an artery or a vein.
The encapsulation of the antimalarial agent, Pyrimethamine
(Daraprim) in silastic polymer and its implantation in chicks was re­
ported by Powers in 1965. According to Powers (1965) implanation
of these slow releasing capsules containing Daraprim protected the
chicks from malaria.
In the field of contraception, Roseman (1974) used silicone
rubber as a matrix for the controlled release of contraceptive steroids.
However, Roseman was more concerned about the mechanisms of the
drug delivery from the silicone rubber and the factors affecting these
mechanisms. His data showed that the structure of the steroid affected
the diffusion of the steroid from the silicone rubber matrices or across
16
the rubber membranes. He also noticed that transport rates were 
dependent upon the degree of lipophilicity of the released steroid and
the thickness of the silicone rubber membrane. Those steroids with
higher silicone solubility generally exhibit faster release rates.
Silicone rubber has also been used for slow release of atropine
and histamine. Bass, et al. (1965) were able to induce longer mydriasis
(pupil dilation) by means of subcutaneous implants of atropine encased
in silastic tubes. They were also able to induce gastrointestinal lesions
in dogs by implanting silastic tubes of histamine at weekly intervals.
Four different formulations of silicone rubber vaginal contracep­
tive devices were designed, fabricated and tested for the release of
controlled doses of three different progestogens: progesterone, norethin-
drone (two dose levels), and d-norgestrel, in 90 day clinical trials by
Burton, et al. (1979). The data obtained with the use of 70 devices
showed that in-vivo release rate from these devices for progesterone 
was 1400 +_ 30 U; norethindrone, 49. 4 _+ 2.4 U; and d-norgestrel, 26. 6 _+
1.4 U. Use of 3 steroid filled silicone rubber devices resulted in nor­
mal ovulation but inhibition of penetration of the cervix by spermatozoa.
Silicone rubber devices filled with high doses of norgesterel also inhi­
bited ovulation.
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Ceramic Implant Delivery Systems
The use of . imics as a biomaterial dates back to 1892. Ac­
cording to Peltier (1961) plaster of Paris was used by Dressman in
1892 to correct bone defects. Various forms of biocompatible and
non-toxic ceramics are in use today. Both resorbable and non-resorb- .
able ceramics have been used as biomaterials to correct defects in the
skeletal system (Hulbert, et al. 1970, 71; Graves, et al. 1971; Young, 1973;
Graves and Noyes, 1974; Graves, et al. 1975 and Mattie, et al. 1981).
Initially Graves, et al. (1971) prepared both single-phase and polyphasic
calcium aluminate ceramic implants. After thirty-two weeks of implana-
tion they observed complete impregnation of the polyphasic ceramic implants
with connective tissue and comparatively no alteration of the single-phase
ceramic material. Graves and Noyes (1974) experimented with calcium
aluminate ceramics containing 5 to 20% phosphorous pentoxide (P2O5).
They reported that the amount of phosphorous pentoxide incorporated
in the calcium aluminate ceramics significantly influenced the surface
characteristics and microstructure of the unimplanted ceramics and
resorption rate of the ceramics implanted in Rhesus monkeys. Toxic,
allergic, or carcinogenic responses were not observed for 2.5 to 3 years
of investigation in any of the animals.
Biochemical, radiographic, scanning-electron-micrographic,
and histological data obtained on calcium aluminate ceramics containing
18
P2O5 suggested that ceramics containing 20% P2O5 were ideal for 
correcting bone defects in rats as well as monkeys (Bajpai, et al. (1976).
Although ceramics have been widely used for orthopaedic and den
tai implantation their use as drug delivery devices has not received much
attention (Khot, et al. , 1980). Khot (1979) fabricated ceramic cylinders
of different porosity and density from a mixture of aluminum, calcium
and phosphorous oxide powders (ALCAP), and used them to deliver in­
sulin (in-vitro) in a static system of phosphate buffered saline at a phy­
siological pH (7.4) and temperature (37°C). The results of this study
showed that the insulin release was affected by the elution time, starting
particle size, and sintering temperature of the ceramics. Sintering
time of the ceramic material alone did not affect the delivery of insulin.
Thus the need for further characterization of ALCAP ceramic reservoirs
is quite obvious.
MATERIALS AND METHODS
The study conducted by Khot (1979) on ALCAP ceramics showed
that these ceramics were capable of delivering insulin in a phosphate- 
buffered-saline (pH 7.4) static system at 37°C. The delivery rate of 
insulin monitored by Khot, et al. (1980) was not affected by the sinter­
ing time of the ceramics. However, the calcined particle size of the
ceramics and the elution time had significant effects on the delivery
of the insulin in the static system. Hence it was considered necessary
to reinvestigate the effect of ceramic particle size on the delivery pro­
file of polypeptides in a continuous flow-through system. Thus for this
investigation ceramics were fabricated from calcined particle sizes of
35-45, 45-60, and 60-75 um by the Department of Material Science of
the University of Dayton using the procedure of Khot, et al. (1980) and
Mattie, et al.(1981) (appendix 6). The ceramics were then used for de­
livering, gamma globulin (150,000 Daltons), bovine serum albumin 
(69,000 Daltons), chymotrypsinogen-A (26,000 Daltons), and insulin
(5, 766 Daltons) in an in-vitro continuous flow-through system of phos­
phate buffered saline (pH 7.4) at 37°C. The delivery of the polypeptides 
and proteins by the ceramic capsules was monitored for seven days and 
the effluent was collected every twenty-four hours. Aliquots from each
19
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day's collection were tested for the presence of proteins in the effluents
by a colorimetric procedure (appendix 5) published by Lowry, et al.
(1951). The data collected were analyzed by means of analysis of vari- •
ance at a significant level of P<^0.05 (Sokal, 1969).
Preparation of Ceramics
Twelve hollow ALCAP ceramic cylinders 2 cm long having an
outside diameter of 1. 3 Cm and inside diameter of 0. 5 cm were fabri­
cated from each of the three ranges of calcined particle size (35-45,
45-60, and 60-75 um) by the procedure of Khot, et al. (1980) and Mat-
tie, al« (1981) (appendix 6). Each ceramic capsule was sintered at 
1425°C (2597°F) for 24 hours. Triplicates of ceramics from each range
of calcined particle size group were used to deliver each of the four poly­
peptides or proteins. For example three ceramics from the 45-60 um
particle size group were tested for delivering gamma globulin (gG).
Each ceramic cylinder was sealed at both ends with silicone rub­
ber sealant (Dow Corning), 24 hours before conducting the experiment.
To avoid denaturation of the polypeptide by heat generated due to the
reaction between water and the ceramic materials, one ml of phosphate
buffered saline (PBS) was injected in the ceramic cavity using an 18G
needle to saturate the ceramic material. A few minutes later, a 0.5 ml
polypeptide solution having a concentration of 100 milligrams per mili- 
liter was injected in each capsule. The punctured end of the capsule
21
was resealed immediately after the injection of the polypeptide solu­
tion (suspension) with the silicone rubber sealant to ensure the release
of the polypeptide through the ceramic pores and not through the punc­
tured end. Although the sealant needs only five minutes to cure it was 
allowed ten minutes to ’’skin off" before the capsule was placed in the 
continuous flow-through system (Fig. 1).
Continuous Flow-Through System:
A circulating water bath, flow-through chamber, peristaltic
pump, PBS reservoir, and collection flasks were assembled into a
continuous flow-through system (Fig. 1).
Chamber;
The chamber is composed of a cylindrical glass cavity (1.5 cm
diameter and 5.5 cm long) andhas three openings. Phosphate buffered
saline enters the main chamber from the bottom opening. The ceramic
capsule containing the polypeptide is placed in the main chamber via
the top opening and it rests on a porous glass disc. The top opening was
later closed by a rubber stopper to prevent evaporation of the fluid in
the chamber. An 18G needle was inserted through the rubber stopper
to equilibrate the chamber pressure with the atmospheric pressure.
The effluent was collected from the side opening. The entire chamber
was jacketed by means of a water jacket. Water from the circulating
water bath was pumped through the water jacket to maintain the tem­
perature of the main chamber at 37°C.
22
Figure 1: A diagramatic representation of the continuous
flow-through system. Basically it consists of 
a buffer reservoir, a peristaltic pump, glass 
jacket around the main chamber for maintaining 
the temperature at 37°C by means of a circulating 
water bath (the ceramic rests on a porous glass 
disc in the main chamber) and the collecting flask.
23
24
Collecting Flasks:
Three hundred mililiter Pyrex flasks (Pyrex No. 4980) were
used for collecting the effluents. Each collecting flask was stoppered
by means of a rubber stopper and connected to the side opening of the
main chamber by means of a polyethylene tubing. The atmospheric pres­
sure of the flask was maintained in the same manner as in the main chamber
Phosphate Buffered Saline (PBS) Reservoir:
A twenty liter plastic tank containing the PBS solution (appendix
5) was connected to a Mini Peristaltic Pump (Markson Science, Inc.,
Del Mar, Ca. 92014). The outlet of the peristaltic pump was connected
to the bottom opening of the main chamber by means polyethylene tubing.
A current of PBS was pumped past the ceramic by means of the peristal­
tic pump at the rate of 0.2 ml/min.
Circulating Water Bath:
A "Lauda Thermostat" circulating water bath (Messgerate-Werk-
Lauda, Western Germany) was connected to the water jacket of the cham 
ber to maintain the temperature at 37°C.
Experimental Procedures:
After the three ceramic capsules containing the polypeptide were
placed in the three chambers, the effluents were collected and the flasks
were changed every twenty four hours for a total period of seven days.
25
Figure 2: Illustration of the sampling procedure. Three ALCAP
ceramics fabricated from each particle size were used 
to deliver each polypeptide for 7 days and 6 aliquots 
from each day's collection were tested for the concen­
tration of proteins.
2 6
R
EP
LI
C
AT
ES
 FR
O
M
C
ER
AM
IC
 
EA
C
H
 
C
O
LL
EC
TI
O
N
S A
FT
ER
 ALIQU
O
TS
 TE
ST
ED
PA
R
TI
C
LE
 SI
ZE
S 
PA
R
TI
C
LE
 SI
ZE
 
EA
C
H
 24
 H
O
U
R
S FOR P
R
O
TE
IN
 C
O
N
C
.
C\J ro in (0
E 000 000
27
Six aliquots of 1 ml each from each day's collection were analyzed by
the procedure of Lowry, et al. (1951) for the presence of proteins and
polypeptides (appendix 5). Known amounts (0-350 mg) of bovine serum •
albumin (BSA.) were used to prepare the standard curve. A "STA.T 10"
computer program (University of Dayton, Computer Library 1981) was
used to obtain linear regression and corrected standard curve from
replicates of BSA standards. A computer program using the corrected
standard curve was written to convert the optical density readings to
miligrams of polypeptide or protein per mililiter of solution. The total
amount of polypeptide for each day's collection was determined by multi­
plying the miligrams of polypeptide per mililiter of solution by the total
amount of effluent (ml) collected (0.2 ml x 1440 min (1 day) = 288 ml/
day).
Measurement of pH:
A. 5 ml aliquot was saved from each day's collection for future
studies and the rest of the effluent was used for determination of pH.
i
Changes in pH were measured in triplicates from each day's collection
by means of a digital ion analyzer (Model No. 801A , Orion .Research,
Inc., Cambridge, Massachusetts 02139).
Data Analysis;
All data collected were analyzed by means of an "AOV" analysis 
of variance computer program (University of Dayton, Computer Library,
28
1981). The effects of the following variables on the release of the
polypeptide from the ceramics were analyzed: (1) elution time in
days, (2) particle size of the ceramics (35-45, 45-60, and 60-75 um),
and (3) ceramic implants. Significant differences between means were
analyzed at P<^0. 05 level using the Student Newman Keuls multiple
range test (appendixes 1, 2, 3, and 4).
RESULTS
Delivery of Gamma Globulin;
Elution pattern of gamma globulin by the three particle size of
ALCAP ceramics has been tabulated in table 1 and presented in Figure 3.
Statistical analysis of the data shows that the delivery rate of gamma
globulin by means of ALCAP ceramics was significantly influenced by
the passage of time as well as the particle size of the ceramics. Dif­
ferences in the amounts of gamma globulin delivered by ceramic repli­
cates were not significant (appendix 1). The delivery rate of gamma globu
lin was inversely proportional to the particle size of the ceramic during
the first two days of elution. On the third and fourth day the highest
amount of gamma globulin was eluted from the ceramics fabricated from
the medium-size particles. The amount of gamma globulin eluted from
the ceramics fabricated from the small and large size particles corres­
ponded to the particle size of the ceramics. During the last three days
the amount of gamma globulin delivered by the ceramics fabricated from
small and medium size particles were not significantly different. Cera­
mics fabricated from the largest particle size delivered the highest
amount of gamma globulin.
Delivery of Bovine Serum Albumin;
Data obtained from the experiments conducted on the delivery of
bovine serum albumin by the three different particle size ALCAP cera­
mic capsules are presented in table 2 and figure 4.
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Figure 3 : The effect of particle size on the delivery profile
of gamma globulin by means of ALCAP ceramic 
capsules in a continuous flow-through system 
(0.2 ml/min) of phosphate buffered saline (pH 7.4) 
at 37°C for a total period of seven days. Each 
point on the graphs represents a mean of eighteen 
replicates + the standard deviation.
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Figure 4: The effect of particle size on the delivery profile
of bovine serum albumin by means of ALCAP 
ceramic capsules in a continuous flow-through 
system (0.2 ml/min) of phosphate buffered saline 
(pH 7.4) at 37°C for a total period of s even days. 
Each point on the graphs represents a mean of 
eighteen replicates + the standard deviation.
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Statistical analysis of the data showed that the elution rate of
bovine serum albumin was significantly influenced by the passage of
time and particle size of the ceramics. During the first three days 
of elution the amount of BSA delivered was directly proportional to 
the ceramic particle size. The amount of BSA eluted during the next
two days from ceramics fabricated from the small and medium size
particles were not significantly different. Ceramics fabricated from
the largest particle size delivered the highest amount of BSA on day
four and five. Particle size of the ceramic did not influence the de­
livery of BSA on the sixth day of elution. Ceramics fabricated from
medium particle size show’ed the highest rate of BSA delivery on the
last day of the experimental trial. Differences between the amount
of BSA delivered by ceramics fabricated from small and large size
particles were not significant. Amount of BSA delivered from repli­
cates were not significant (appendix 2)
Delivery of Chymotrypsinogen-A:
Milligrams of chymotrypsinogen-A delivered by ALCAP cera­
mics fabricated from three different particle sizes for a period of
seven days are shown in table 3, and figure 5.
Analysis of variance and range test of the data showed that both
particle size of the ceramics and the elution time have a significant effect
on the delivery rate of chymotrypsinogen-A from the ALCAP ceramics.
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Figure 5: Effect of particle size on the delivery profile 
of chymotrypsinogen-A by means of ALCAP 
ceramic capsules in a continuous flow-through 
system (0.2 ml/min) of phosphate buffered 
saline (pH 7.4) at 37°C for a total period of 
seven days. Each point on the graphs represents 
a mean of eighteen replicates the standard de­
viation.
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The delivery rate of chymotrypsinogen-A on the first day of
the experiment was directly proportional to the starting particle size 
of the ceramics. On the second day there was no significant difference 
in the amount of chymotrypsinogen delivered by small and medium par­
ticle size ceramics. The amount of chymotrypsinogen-A deliver­
ed by the large particle size ceramics was significantly lower than the
amount of chymotrypsinogen-A delivered by small and medium particle
size ceramics. On the third day the lowest amount of chymotrypsino­
gen-A was delivered by the smallest particle size ceramics and the
largest amount of chymotrypsinogen-A was delivered by the largest
particle size ceramics. During the last four days although the statis­
tical analysis showed differences in the amount of chymotrypsinogen-A
delivered by the three different particle size ceramics it is apparent
that the amounts of chymotrypsinogen-A delivered were too small and
similar for logical interpretation.
Except for day to day variation the delivery profile of gamma
globulin, bovine serum albumin, and chymotrypsinogen-A seems to
follow a similar pattern.
Delivery of Insulin
The insulin data presented in table 4 and figure 6 shows that
both ceramic particle size and passage of time significantly influenced
the delivery rate of insulin. Differences in the amount of insulin deli­
vered by ceramic replicates were not significant (appendix 4).
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Figure 6: Effect of particle size on the delivery profile of 
insulin by means of ALCAP ceramic capsules in 
a continuous flow-through system (0.2 ml/min) 
of phosphate buffered saline (pH 7.4) at 37°C 
for a total period of seven days. Each point on 
the graphs represents a mean of eighteen repli­
cates 4 the standard deviation.
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The amount of insulin released during the first two days by all 
the ceramics was significantly lower than the amount of insulin released 
during the next three days. The large particle size ceramics released 
the largest amount of insulin during the first four days of the trial. Dif­
ferences in the amount of insulin released by small and medium particle 
size ceramics were not significant for the first two days and days four
and five of the trial. A drop in the amount of insulin released took place
after the fourth day in the case of largest particle size ceramics (60-75
um) and after the fifth day from small and medium particle size ceramics
(35-45 and 45-60 um). The amount of insulin eluted from the largest par­
ticle size ceramic on days three and four were not significantly different
and the amount of insulin eluted from the small and medium particle size
ceramics were not significantly different. Up to the fourth day the deli­
very rate of insulin was directly proportional to the particle size. An
inverse relationship between these two parameters seemed to take place
during the last three days of the trial.
pH Data
Tables 5, 6, 7, and 8 show the pH of the phosphate buffered saline
effluent on each day of the four trials conducted with different proteins
in this investigation. After the initial drop in pH from 7.4 to 7.3 the
range of pH changes in effluents collected from ceramic reservoirs
containing gamma globulin, bovine serum albumin or chymotrypsinogen
varied from 7.30 to 7.32 (tables 5-7). The range of pH change in effluents
45
collected from ceramic reservoirs containing insulin varied from 7.30
to 7.33 (table 8). Although the original pH shifted from 7.4 to 7.3 dur­
ing the course of each trial, ceramic replicates, ceramic particle size,
the nature of protein, and passage of time did not influence the pH of the
effluent.
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DISCUSSION
In vitro data of Khot, et al. (1980) showed that insulin could be
delivered by means of porous ceramics in a static system. Khot, et al. 
(1980) also suggested that by varying the particle size of the ceramic 
one can tailor the pore size and thus the delivery of substances of vari­
ous molecular weights.
In vitro and in vivo studies conducted by Mattie, et al. (1980)
and Bajpai, et al. (1976) have shown that ALCAP ceramics are resorb­
able, hence with passage of time the pore size of the ceramic should
increase and compensate for the decrease in concentration of the sub­
stance in the reservoir by increasing the flow rate of the substance
from the ceramic. Since ceramics are biocompatible and are porous
in nature, it is logical to assume that they can deliver polypeptides or
other substances of various molecular weights.
In my opinion there are three main forces responsible for de­
livering the polypeptides from the ceramic reservoir to the surrounding
buffer medium: (1) concentration gradient between the ceramic cavity
and the surrounding medium, (2) pressure developed within the ceramic
cavity due to drawing in of the phosphate buffer saline by means of os­
motic tension, and (3) the surface tension drag created by the phosphate
50
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buffer saline flowing past the ceramic. On the other hand the opposing
forces probably are: (1) absorptive nature of the ceramic particles,
(2) trapping process of polypeptide molecules within the micropores
between the ceramic particles, (3) adherence between polypeptides and
ceramic particles due to interaction between charges of the proteins
and ceramic components, (4) degree of viscosity displayed by each
protein, and (5) probably the molecular size of the various proteins.
All of these postulates seem to be confirmed by the statistical
analysis of the collected data (appendixes 1-4). Differences due to
particle size and passage of time were evident. Differences due to
nature of proteins were observed. No significant differences due to
ceramic replicates were observed. Interactions between ceramic repli­
cates and the different days were not significant except in some instances
of protein delivery by the smallest particle size ceramics. The scanning
electron micrographs of the cracked surface of a ceramic fabricated
from the smallest particle size of 35-45 um (Fig. 7) shows the distri­
bution of micro and macropores within the ceramic between sintered
ceramic particles. The rate of gamma globulin delivery (Figs. 8-11)
during the first two days was lower than the bovine serum albumin
and chymotrypsinogen-A. Since the gamma globulin molecules are
much larger and more viscous than the molecules of bovine serum 
albumin it appears that it takes almost two days for its molecules to 
saturate the macropores of the ceramics, after which the molecules 
are simply excluded due to differences in concentration gradient between
52
Figure 7: Scanning electron micrographs (25 OX) of a 
cracked surface of ALCAP ceramics fabri­
cated from 35-45 um sized particles sintered 
at 1425°C for 24 hours showing the distribution 
of micropores and macropores within the cera­
mics. ( Reproduced with a permission of D. R. 
Mattie, University of Dayton, Dayton, Ohio).
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Figure 8: Delivery profiles of gamma globulin, bovine 
serum albumin, chymotrypsinogen-A and in­
sulin by ALCAP ceramic capsules fabricated 
from particle sizes ranging between 35 and 45 
micrometers. The delivery took place in a 
continuous flow-through system (0.2 ml/min) of 
phosphate buffered saline (pH 7.4) at 37°C 
for a total period of seven days. Each point 
on the graphs represents a mean of eighteen 
replicates + the standard deviation.
55
TIME OF DELIVERY (DAYS)
56
Figure 9: Delivery profiles of gamma globulin, bovine 
serum albumin, chymotrysinogen-A, and in­
sulin by ALCAP ceramic capsules fabricated 
from particle sizes ranging between 45 and 60 
micrometers. The delivery took place in a 
continuous flow-through system (0.2 ml/min) 
of phosphate buffered saline (pH 7.4) at 37°C 
for a total period of seven days. Each point 
on the graphs represents a mean of eighteen 
replicates + the standard deviation.
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Figure 10: Delivery profiles of gamma globulin, bovine
serum albumin, chymotrypsinogen-A, and in­
sulin by ALCAP ceramic capsules fabricated 
fromparticle sizes ranging between 60 and 75 
micrometers. The delivery took place in a 
continuous flow-through system (0.2 ml/min) 
of phosphate buffered saline (pH 7.4) at 37°C 
for a total period of seven days. Each point 
on the graphs represents a mean of eighteen 
replicates + the standard deviation.
59
TIME OF DELIVERY (DAYS)
60
Figure 11; Effect of particle size on the amount of gamma 
globulin retained by ALCAP ceramic capsules 
placed in a continuous flow-through system 
(0.2 ml/min) of phosphate buffered saline (pH 7.4) 
at 37°C for a total period of seven days. Each 
point on the graphs represents a mean of eighteen 
replicates + the standard deviation.
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the ceramic cavity and the surrounding buffer medium, and the surface
tension drag created by the flowing of the buffer past the ceramic. The
exclusion patterns of the bovine serum albumin (table 2, and figs. 8-
10, and 12) and chymotrypsinogen-A (table 3, and figs. 8-10 and 13)
were typical of chromatographic type of exclusion. However, after
the first day of exclusion the amount of protein (gamma globulin, bo­
vine serum albumin, and chymotrypsinogen-A) retained within the
ceramic (figs. 11-13) started to govern the delivery profile of each
polypeptide. The lower release of insulin during the first day of the
J
trial could be due to the small molecular size of the insulin (figs. 8-
10, and 14). Delay in the release of insulin molecule is probably due
to the trapping of the molecules in the micropores of the ceramic ma­
terial. This hypothesis seems to be confirmed by exponential phase of
insulin release during the next two or three days of the experiment.
The increase in insulin delivery in the following days is probably due
to the saturation of the branched spaces between the ceramic particles
by insulin molecules. This concept is supported by the leveling off of
insulin delivery for a period of one day. The ensuring decrease in the
rate of insulin delivery during the last three days of the experiment
is probably due to the drop in concentration gradient and decrease in
the amount retained in the ceramic reservoir (fig. 14). The pore
63
Figure 12: Effect of particle size on the amount of bovine
serum albumin retained by ALCAP ceramic 
capsules placed in a continuous flow-through 
system (0.2 ml/min) of phosphate buffered 
saline (pH 7.4) at 37°C for a total period of 
seven days. Each point on the graphs repre­
sents a mean of eighteen replicates +_ the stan­
dard deviation.
64
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Figure 13: Effect of particle size on the amount of chymo-
trypsinogen-A retained by ALCAP ceramic 
capsules placed in a continuous flow-through 
system (0.2 ml/min) of phosphate buffered 
saline (pH 7.4) at 37°C for a total period of 
seven days. Each point on the graphs repre­
sents a mean of eighteen replicates 4. the stan­
dard deviation.
66
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Figure 14: Effect of particle size on the amount of Insulin
retained by ALCAP ceramic capsules placed in 
continuous flow-through system (0.2 ml/min) of 
phosphate buffered saline (pH 7.4) at 37°C for a 
total period of seven days. Each point on the 
represents a mean of eighteen replicates _+ the 
standard deviation.
68
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sizes of the ceramics fabricated from 35-45, 45-60, and 60-75 um 
size particles were 13. 5 +_2,2, 27. 6 + 3.1, and 32.3 +_ urn respec­
tively (Figs. 7, 15 and 16). There is a direct relationship between
the particle size and the pore size of the ceramic material. However
it is also obvious that the number of macro pores per unit volume are
inversely proportional to the particle size of the ceramic material.
If the ceramics are behaving as chromatograph columns the direct
relationship between the pore size and the particle size suggests that
larger polypeptides should be excluded more rapidly by the smaller
particle size ceramics and smaller peptides should be retained longer
by the larger particle size ceramics. However, the largest amount
of insulin was delivered by the largest particle size ceramics and this
can be explained by the second relationship between the particle size
and the number of pores per unit volume. It appears that the delay of
the insulin delivery is affected not only by the trapping of the insulin
molecules in the micropores of the ceramic material but also by the
number of these pores per unit volume which means that the trapping
process increases as the number of the micropores increase and mac­
ropores decrease per unit volume. The scanning electron micrographs
of the medium and large particle size ceramics (Figs. 15 and 16) show
less number of micropores, than that of the smallest particle size
ceramics (Fig. 7). In short, delivery pattern of insulin (Table 4, 
and Figs. 8-10, and 14) suggests that the insulin molecules are either
70
Figure 15: Scanning electron micrographs (250X) of a 
cracked surface of ALCAP ceramics fabri­
cated from 45-60 um sized particles sintered 
at 1425°C for 24 hours showing the distribution 
of the micropores and macropores within the 
ceramics. (Reproduced with a permission from 
D. R. Mattie, University of Dayton, Dayton, Ohio).
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Figure 16: Scanning electron micrographs (250X) of a 
cracked surface of ALCAP ceramics fabri­
cated from 60-75 um sized particles sintered 
at 1425°C for 24 hours showing the distribution 
of the micropores and macropores within the 
ceramics (reproduced with a permission from 
D. R. Mattie, University of Dayton, Dayton, 
Ohio).
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trapped within the micropores or absorbed onto the ceramic particles
for longer duration than the larger molecular weight polypeptides.
This in turn allowed the insulin molecules to be delivered in a rela­
tively sustained manner. Once again after the bulk of the polypeptide
has been delivered during the first four days, the amount of insulin
retained within the ceramic cavity (Fig. 14) starts to influence the
delivery pattern. The delivery rate of bovine serum albumin (Table 2,
and Fig. 12) increased by the decrease in the number of micropores.
It is possible that the trapping process of the bovine serum albumin
molecules within the micropores had the greatest effect on its delivery
rate. The scanning electron micrograph of the largest particle size
ceramics (Fig. 16), shows the least number of macropores. The rate
of delivery of gamma globulin was the slow’est by ceramics fabricated
from the larger size particles (Table 1, and Fig. 11). This suggests
that the molecules were excluded more slowly from ceramics contain­
ing less number of macropores. It is possible that the gamma globulin
molecules were absorbed onto the larger particles for a longer time.
Both viscosity and interaction of charges between the protein molecules
and the ceramic particles could be responsible for this phenomenon.
The pH of the phosphate buffered saline effluent passing the
ceramic capsules in the continuous flow-through system was not affected
by any of the three variables: elution time; ceramic particle size; or the
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molecular weight of the various polypeptides or proteins (Tables 5,
6, 7 and 8). However, the original pH shifted from 7.4 to 7.3 during
the continuous flow studies. In the studies conducted by Khot, et al.
(1980), and Mattie et al. (1981) with ceramics in static systems, it
was obvious that the pH of the phosphate buffered saline or plasma
(respectively) always shifted toward the alkali side. This change in
pH was attributed to the rapid release of the hydroxyl ions from the
ceramic into the effluent. Rapid replacement of the buffer medium
in the continuous flow system probably prevented the accumulation of
hydroxyl ions in this system. Since the pH of phosphate buffered saline
with and without ceramics in the buffer changed from 7.4 to 7. 3 it is
likely that the carbon dioxide (CO2) from the air coming through the
18G needle into the phosphate buffered saline solution was responsible
for shifting the pH toward the acid side.
CONCLUSION
The data obtained from this investigation suggests that ALCAP
ceramic reservoirs (capsules) can deliver polypeptides of various mole
cular weights. The ceramic reservoirs do not act as simple filtering
devices but more like chromatographs and that the delivery of each pep
tide is governed by (1) the physical nature of the polypeptide, (2) the
size of particles from which the ceramic was fabricated, and (3) the
concentration gradient as determined by the amount of protein retained
within the ceramic resevoir.
In short the ceramic reservoirs can be used as in-vivo depots
for delivering active forms of polypeptides and proteins.
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APPENDIX (1)
A
Analysis of variance tables for determination of significant differences
(at P<0.05) among particle sizes and ceramic replicates during the
delivery of Gamma Globulin (mg) by ALCAP ceramics in a continuous
flow-through system of phosphate buffered saline (ph 7.4) at 37°C for
a period of seven days.
Abbreviation Key
S.S. = Sum of squares
D.F. = Degrees of freedom
M. S. = Mean of Squares
Cer. Rep. = Ceramic capsule replicates
Part. Size = Ceramic particle size (Mm)
LSR = Least significant range.
K = The number of items over which the range is computed.
N = Number of data point used to determine the calculated value.
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DAY (1)
F actors S.S. D. F. M.S. P F-ratio
Part. Size 471.176 2 235.588 0. 13 x 10"7 1272. 190*
Cer. Rep. 1.111 6 0. 185 0. 019 2.864 *
E rror 2. 910 45 0. 065
Particle Size (u m)
Cer. Rep. 35 -45 45-60 60-75
(mg) (mg) (mg)
1 17. 2 + 0.2 15. 3 + 0. 3 10. 5 + 0.4
2 17. 7 + 0.2 15. 5 + 0. 3 10. 3 + 0.3
3 17. 5 + 0. 3 15.2 + 0. 0 10. 5 + 0.2
MEAN 17. 5 + 0.3 15. 3 + 0.3 10.4 + 0. 3
+ = Significant at P<0. 05
NS = Not significant at P<0. 05
K 2 3
Cer. Rep.
LSR
Part. Size
0.3 (mg) 0.4 (mg)
0. 2 (mg) 0. 2 (mg)
N for the mean =18
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DAY (2)
F actors S.S. D.F. M.S. P F-ratio
Part. Size 84.342 2 42. 171 0.216 x 10“5 229.099 *
Cer. Rep. 1.104 6 0.184 0. 067 2.140 NS
Error 3.870 45 0. 086
Cer. Rep. 35-45
Particle Size (um)
45-60 60-75
1
(mg)
16.6 + 0.3
(mg)
15. 7 + 0.4
(mg)
13.4 + 0.3
2 16. 6 + 0.2 15.5 +0.3 13.3 + 0.1
3 16.3 + 0.2 15.4 + 0.2 13.8 + 0.2
MEAN 16. 5 + 0.3 15.5 +0.3 13.5 + 0.3
* = Significant at P<0. 05 
NS = Not significant at P< 0. 05
K 2 3
Cer.Rep. 0.3 (mg) 0.4(mg)
LSR
Part. Size 0.2(mg) 0.2 (mg)
N for the mean = 18
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DAY (3)
F actors S.S. D.F. M.S. F-ratio
Part. Size 90. 803 45.402 0. 12 x 10 -6 605.359
Cer. Rep. 0.450 6 0. 075 0.442 0.993
Error 3.400 45 0. 076
Particle Size (um)
Cer. Rep. 35-45 45-60 60-75
(mg) (mg) (mg)
1 6.5 + 0.3 9o 4 + 0.2 8 a 8 + 0.2
2 6.3 + 0.4 9. 6 + 0o 3 8.7 + 0.3
3 6.5 + 0.2 9. 5 + 0.3 8.6 + 0.2
MEAN 6.5 + 0.3 9. 5 + 0.3 8.7 + 0.2
* = Significant at P<0. 05
NS = Not significant at P<0.05
K 2 3
Cer. Rep. 0. 3 (mg) 0.4 (mg)
LSR
Part. Size 0. 2 (mg) 0. 2 (mg)
N for the mean = 18
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DAY (4)
F actors S.S. D.F. M.S. P F-ratio
Part. Size 43.858 2 21.929 0. 11 x IO"5 288.817 *
Cer. Rep. 0.456 6 0. 076 0. 334 1. 187 NS
Error 2. 897 45 0. 064
Particle Size (um)
Cer. Rep. 35 -45 45-60 60-75
(mg) (mg) (mg)
1 3.7 + 0.3 5. 6 + 0.2 5.4 + 0.2
2 3.6 + 0. 1 5.5 + 0.2 5.3 + 0.3
3 3.5 + 0.4 5.7 + 0.3 5.6 + 0.2
MEAN 3. 5 + 0.3 5. 6 + 0.2 5.4 + 0. 3
* = Significant at P<0.05 
NS = Not significant at P< 0. 05
K 2 3
Cer.Rep. 0.3 (mg) 0.4(mg)
LSR
Part. Size 0.2 (mg) 0.2 (mg)
N for the mean = 18
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DAY (5)
F actors S.S. D. F. M.S. P F-ratio
Part. Size 91.863 2 45.932 0. 14 x 10"6 574.152 4
Cer. Rep. 0.480 6 0. 080 0.418 1.031 NS
Error 3.492 45 0. 078
Particle Size (um)
Cer. Rep. 35-45 45-60 60-75
(nig) (mg) (mg)
1 1.4 4 0.2 1.7 4 0.3 4.3 4 0.3
2 1.6 4 0. 1 1.5 4 0.3 4. 5 4 0.4
3 1.7 4 0.1 1. 5 4 0.1 4,2 + 0.4
MEAN 1. 6 4 0.2 1.6 4 0.3 4.4 4 0.4
4 = Significant at P<0. 05
NS = Not significant at P<0. 05
K 2 3
Cer. Rep. 0.3 (mg) 0.4 (mg)
LSR
Part. Size 0.2 (mg) 0.2 (mg)
N for the mean = 18
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DAY (6)
F actors S.S. D.F. M.S. P F-ratio
Part. Size 106.045 2 53.022 0.993 x 10"7 644.866 *
Cer. Rep. 0.493 6 0. 082 0.236 1.399 NS
Error 2. 645 45 0.059
Particle Size (um)
Cer. Rep. 35-45 45-60 60-75
(mg) (mg) (mg)
1 0.5 + 0.3 0, 4 4 0.2 3.4 + 0.3
2 0. 2 + 0.0 0.4 4 0.3 3. 2 + 0.3
3 0. 2 + 0. 1 0. 5 + 0.3 3. 4 + 0.2
MEAN 0. 3 + 0.2 0. 5 + 0. 3 3- 3 + 0. 3
* = Significant at P<0. 05 
NS = Not significant at P<0. 05
K 2 3
Cer. Rep.
LSR
Part. Size
0. 3 (mg) 0. 3 (mg)
0.2 (mg) 0.2 (mg)
N for the mean = 18
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DAY (7)
F actors S.S. D.F. M.S. P F-ratio
Part. Size 19.563 2 9.782 0.27 x 10"6 463.345 *
Cer. Rep. 0. 127 6 0. 021 0. 684 0. 657 NS
Error 1.445 45 0.032
Particle Size (um)
Cer. Rep. 35-45 45-60 60-75
1
(mg)
0.2 + 0. 1
(mg)
0.4 + 0.3
(mg)
1.4 + 0.2
2 0.2 + 0.2 0.5 + 0. 1 1.6 + 0.2
3 0.2 + 0. 1 0.4 + 0.2 1. 5 + 0.2
MEAN 0.2 + 0. 1 0.4 + 0.2 1.5 + 0.2
* = Significant at P<0. 05 
NS = Not significant at P<0. 05
K 2 3
Cer. Rep. 0. 2 (mg) 0. 3 (mg)
LSR
Part. Size 0. 1 (mg) 0. 2 (mg)
N for the mean = 18
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Analysis of variance tables for determination of significant differences 
(at P<0. 05) among: Days, Ceramic Replicates, and Interaction between
Days and Ceramic Replicates during the Delivery of Gamma Globulin (mg)
by ALCAP ceramics in 
buffered saline (pH 7.4)
a continuous flow-through system of phosphate
at 37°C.
F-ratio
Particle Size
F actors
35-45 um
S.S. D.F. M.S. P
Day 5974.810 6 995.802 0.397 x IO'19 5963.93 *
Cer. Rep. 0. 076 2 0. 038 0.489 0. 721 NS
Cer. Rep. x 
Days 2.004 12 0. 167 0. 724 x IO-3 3.154 *
Error 5. 558 105 0. 053
Particle Size 45-60 um
F actors S.S. D.F. M.S. P F-ratio
Days 4799.32 6 799.887 0. 399x 10-21 12844.8 *
Cer. Rep. 0. 105 2 0. 053 0.458 0. 786 NS
Cer. Rep. x 
Days 0. 747 12 0. 062 0. 517 0. 933 NS
Error 7. 008 105 0. 067
Particle Size 60-75 um
F actors S.S. D.F. M.S. P F-ratio
Days 1967.78 6 327.964 0. 21 x 10"17 3076.2 *
Cer. Rep. 0. 144 2 0. 072 0.400 0. 924 NS
Cer. Rep. X 
Days 1.279 12 0. 107 0. 193 1.368 NS
Error 8. 185 105 0. 078
S.S. = Sum of squares * = Significant at P^0. 05
D.F. = Degrees of freedom NS = Not significant at P<0.05 
M.S. = Mean of squares
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Appendix 1-C
Comparison Among Means by Student Newman Keuls Test on 
Amount of Gamma Globulin (mg) Delivered by the different 
particle sizes of ALCAP ceramics in a continuous flow-through 
system of phosphate buffered saline (pH 7.4) at 37°C on each 
day for a period of seven days.
DAYS MEANS OF AMOUNT DELIVERED
(1) 10.4^ 15.3m 17.5s
(2) 13. 5L 15.3 16.5s
(3) 6. 5s 8.7L 9.5m
(4) 3.- 5s 5.4L 9. 7m
(5) 1. 6s 1.6m 4. 4L
(6) 0. 3s 0.5m 3.3L
(7) 0.2s 0.4m 1.5L
s = Particle size 35-45 um 
m = Particle size 45-60 um 
L = Particle size 60-75 um
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APPENDIX (2)
A
Analysis of variance tables for determination of significant differences
(at P<0.05) among particle sizes and ceramic replicates during the deli
very of bovine s erum albumin (mg) by ALCAP ceramics in a continuous
flow-through system of phosphate buffered saline (pH 7.4) at 37°C for
a period of seven days.
Abbreviation Key
S.S. = Sum of squares
D.F. = Degrees of freedom
M.S. = Mean of Squares
Cer. Rep. = Ceramic capsule replicates
Part. Size = Ceramic particle size (Mm)
LSR = Least significant range.
K = The number of items over which the range is computed.
N = Number of data point used to determine the calculated value.
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DAY (1) 
A NOVA
F actors S.S. D.F. M.S. P. F
Part. Size 395.536 2 197.768 0.24 x IO”8 2234.27 *
Cer. Rep. 0. 531 6 0. 089 0.454 0. 974 NS
Error 4. 090 45 0. 091
Cer. Rep.
35-45
Particle Sizes (um) 
45-60 60-75
(mg) (mg) (mg)
1 17. 5 + 0. 3 23.6 + 0.1 22.7 + 0.3
2 17. 3 + 0.2 23.5 + 0.3 22.6 +0.3
3 17.5 + 0.3 23.5 + 0. 2 22.5 + 0.3
Mean 17.4 +0.3 23.5 + 0.3 22.6 +0.3
* = Significant at P<0. 05 
NS = Not significant at P<0. 05
K 2 3
Cer. Rep. 0.4 (mg) 0.4 (mg)
LSR
Part. Size 0.2 (mg) 0. 3 (mg)
N for mean = 18
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DAY (2) 
A NOV A
F actors S.S. D.F. M.S. P. F
Part. Size 438.922 2 219.461 0.598 x 10"8 16.49.73 *
Cer. Rep. 0. 798 6 0. 133 0. 903 0.518 NS
E rror 3. 102 45 0. 069
Cer. Rep.
35-45
Particles (nm) 
45-60 60-75
1
1
7. 5
(mg)
+ 0.2
(mg)
10.3 + 0.3
(mg)
14. 6 + 0. 1
2 7. 6 + 0.3 10.4 + 0.3 14.4 + 0.2
3 7. 3 + 0. 1 10. 5 + 0.3 14.3 + 0.2
Mean 7.4 + 0.3 10.5 + 0.3 14.4 + 0.2
* = Significant at P<0.05 
NS = Not significant at P<0. 05
K
Cer. Rep.
LSR
Part. Size
2
0.3 (mg)
0.2 (mg)
3
0.4 (mg)
0.2 (mg)
N for mean = 18
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DAY (3)
ANOVA
Factors S.S. D.F. M .S. P. F
Part.Size 35. 335 2 17. 668 0. 130 x 10 124.672*
Cer. Rep. 0. 850 6 0. 142 0. 908 0.511 NS
Error 3.257 45 0. 072
Cer. Rep. Particle Sizes (um)
35-45 45-60 60-75
(mg) (mg) (mg)
1 2.4 + 0.3 3.4 + 0. 1 4.7 + 0.3
2 2.7 + 0. 2 3.4 + 0.3 4. 5 + 0.2
3 2.5 + 0.2 3.5 + 0.2 4.3 + 0. 3
Mean 2.5 + 0.3 3.4 + 0.3 4.5 + 0.3
~~
* = Significant at P<0. 05
NS = Not significant at P<0. 05
K 2 3
Cer. Rep. 0.3 (mg) 0.4 (mg)
LSR
Part. Size 0.2 (mg) 0.2 (mg)
N for the mean =18
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DAY (4)
F actors S.S. D. F. M.S. P F
Part. Size 15.225 2 7. 613 0.61 x 10“3 32.475+
Cer. Rep. 1.410 6 0.234 0. 998 0. 232 NS
Error 2.452 45 0.055
Cer. Rep.
35-45
(mg)
1.2 +0.3
Particle Sizes (um) 
45-60____
(mg)
1.6 + 0. 3
60-75
(mg)
2.5 + 0.31
2 1.7 + 0.3 1.4 + 0.2 2.5 + 0.3
3 91.5 + 0.2 1.2 + 0. 3 5 + 0.3
Mean 1.5 +_ 0.3 1.4 +_ 0. 3
* = Significant at P<0. 05
NS = Not significant at P<0.05
2.5 + 0.3
K
Cer. Rep.
LSR
2
0. 3 (mg)
Part. Size 0.2 (mg)
3
0. 3 (mg)
0.2 (mg)
N for mean =18
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DAY (5)
ANOVA
Factors S.S. D.F. M.S. P. F
Part. Size 16.883 2 8.441 0. 137 x 10“4 122.534
Cer. Rep. 0.413 6 0. 069 0. 031 2.555
Error 1.203 45 0. 027 0. 031
Cer. Rep. Particle Sizes (um)
35--45 45-60 60-75
(mg) (mg) (mg)
1 0.2 + 0. 0 0.2 + 2 1.5 + 0.3
2 0.2 T 0. 0 0.2 + 1 1. 5 + 0.2
3 0.2 + 0. 1 0.2 4 0 1.2 + 0.3
Mean 0. 2 + 0. 0 0.2 + 0. 1 1.4 + 0.3
* - Significant at P<C0. 05
K 2 3
LSR
Cer. Rep. 0. 2 (mg) 0- 2 (mg)
Part. Size 0. 1 (mg) 0. l(mg)
N for the mean = 18
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DAY (6)
F actors S.S. D.F. M.S. P F
Part. Size 0. 019 2 0.0096 0. 196 2. 167 NS
Cer. Rep. 0. 027 6 0.0044 0. 004 3. 75 *
Error 0. 053 45 0.0012
Cer. Rep.
35-45
Particle Sizes fum)
45-60 60-75
(mg) (mg) (mg)
1 0.3 + 0. 1 0. 1 + 0.0 0.2 + 0. 0
2 0. 2 + 0.0 0.2 + 0.0 0.2 4 0. 1
3 0.2 + 0.0 0. 2 + 0.0 0.2 + 0.0
Mean 0. 2 j- 0. 0
* = Significant at P^O. 05 
NS = Not significant at P<0. 05
K 2
0.2 + 0.0 0.2 + 0. 0
3
Cer. Rep.
LSR
Part. Size
0-0 (mg)
0.0 (mg)
0. 0 (mg)
0. 0 (mg)
N for the mean =18
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DAY (7)
ANOVA
F actors S.S. D.F. M. S. P, F
Part. Size 0. 058 2 0.029 0. 237 x IO"2 19.500 *
Cer. Rep. 0.009 6 0.0015 0. 43 7 1 NS
Error 0.067 45 0. 0015
Cer. Rep.
35-45
Particle
45
Sizes
-60
(um)
60 -75
1
(mg)
0. 1 + 0.0
(mg)
0.2 + 0. 0
(mg)
0.2 + 0. 0
2 0. 1 + 0.0 0.2 + 0. 0 0.2 + 0.0
3 0. 1 + 0.0 0.2 + 0. 0 0.2 + 0. 0
Mean 0. 1 + 0.0 0.2 + 0. 0 0.2 + 0. 0
* = Significant at P<0. 05 
NS - Not significant at P<0. 05
K 2 3
Cer. Rep. 0. 0 (mg) 0.0 (mg)
LSR
Part. Size 0.0 (mg) 0.0 (mg)
N for the mean =18
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Analysis of variance tables for determination of significant differences 
(at P<0.05) among: Days, Ceramic Replicates, and Interaction between 
Days and Ceramic Replicates during the Delivery of Gamma Globulin (mg) 
by ALCAP ceramics in a continuous flow-through system of phosphate 
buffered saline (pH 7.4) at 37°C.
Particle Size 35-45 um
F actors S. S. D. F. M.S. p F-ratio
Days 4384.79 6 730.799 0. 256 x io-19 6417.6 *
Cer. Rep. 0. 1535 2 0.0768 0. 118 2. 182 NS
Days x
Cer. Rep. 1. 3665 12 0. 1139 0.548 x IO’3 3.237 *
Error 3. 6933 105 0.0352
Particle Size 45-60 um
F actors S.S. D. F. M. S. p F-ratio
Days 8191. 11 6 1365.18 0.961 x 10”24 35081.3 *
Cer. Rep. 0.01481 2 0.0074 0.8745 0.1347 NS
Day x
Cer. Rep. 0.4670 12 0.0389 0.7408 0. 7077 NS
Error 5. 774 105 0.0550
Particle Size 60-75 um
F actors S.S. D.F. M.S. P F-ratio
Days 8089.73 6 1348.29 0.150 x 10-22 22178.1 *
Cer. Rep. 0. 661 2 0.330 0. 305 x 10"2 6. 123 *
Days x
Cer. Rep. 0. 730 12 0. 061 0.347 1. 127 NS
Error 5. 663 105 0. 054
S.S. = Sum of Squares 
D. F. = Degrees of freedom 
M.S. = Mean of Squares
* = Significant at P<0. 05 
NS = Insignificant at P<0.05
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Comparison Among Means by Student-Newman Keuls Test on Amount 
of Bovine Serum Albumin (mg) Delivered by the Different Particle Sizes 
of ALCAP Ceramics in a Continuous Flow-Through System of Phosphate 
Buffered Saline (pH 7.4) at 37°C on each day for a period of seven days.
DAYS MEANS OF AMOUNT DELIVERED
1 17.4s 22. 6L 23.5m
2 7.4s 10.5m 14.4L
3 2.5s 3.4m 4. 5L
4 1.4m 1.5s 2.5L
5 0.2s 0.2m 1.4L
6 0.2s 0.2m 0. 2L
7 0. Is 0. 1L 0.2m
s = Particle Size 35-45 um
m - Particle Size 45-60 um
L = Particle Size 60-75 um
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APPENDIX (3)
A
Analysis of variance tables for determination of significant differences 
(at P<0.05) among particle sizes and ceramic replicates during the deli 
very of chymotrypsinogen (mg) by ALCAP ceramics in a continuous
flow-through system of phosphate buffered saline (pH 7.4) at 37°C for
a period of seven days.
Abbreviation Key
S.S. = Sum of squares
D. F. = Degrees of freedom
M. S. = Mean of Squares
Cer.Rep. = Ceramic capsule replicates
Part. Size = Ceramic particle size (Mm)
LSR = Least significant range.
K = The number of items over which the range is computed.
N = Number of data point used to determine the calculated value.
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DAY (1)
Factors S.S. D.F. M.S. P F-ratio
Part. Size 91.813 2 45.907 0. 18 x 10‘6 528. 579 *
Cer. Rep. 0.521 6 0. 869 0. 103 1.891 NS
Error 2.067 45 0.459
Particle Size (um)
Cer. Rep. 35-45 45-60 60-75
(mg) (mg) (mg)
1 25. 7 + 0.2 26. 8 + 0.2 28. 9 + 0.0
2 25. 4 + 0.2 26. 7 + 0.2 28. 7 + 0. 3
3 25. 6+0.2 26. 8 + 0.2 28. 7 + 0.3
MEAN 25. 6 + 0.2 26. 8 + 0.2 28. 7 + 0.2
* = Significant at P<0. 05
NS = Not s ignificant at P<0. 05
K_ 2 3_
Cer. Rep. 0. 8 0(mg) 1.00 (mg)
LSR
Part. Size 0. 50(mg) 0. 60 (mg)
N for the mean = 18
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DAY (2)
F actors S.S. D.F. M.S. P F-ratio
Part. Size 14.450 2 7.220 0.219 x 10“5 228.084 *
Cer. Rep. 0. 190 6 0. 032 0. 853 0.434 NS
Error 3.290 45 0.073
Particle Size (um)
Cer. Rep. 35-45 45-60 60-75
1
2
3
MEAN
(mg)
13.6 + 0.3
13.6 + 0. 3
13.5 + 0. 3
13. 6 + 0.3
(mg)
13.5 + 0.2
13.4 + 0.3
13. 5 + 0. 3
13.4 + 0. 2
(mg)
12.5+0.3
12.3 +0.3
12.4 + 0.3
12.4 +0.3
* = Significant at P<0.05 
NS = Not significant at P<0. 05
K 2
Cer. Rep.
LSR
Part. Size
0.30 (mg) 0. 40 (mg)
0.20 (mg) 0.20 (mg)
N for the mean = 18
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DAY (3)
D.F. M.S. P ' F-ratioFactors S.S.
Part. Size 77.950 2 38.980 0.39 x 10“7 880.62 *
Cer. Rep. 0.270 6 0.044 0.69 0. 654 NS
Error 3. 060 45 0. 068
Particle Size (um)
Cer. Rep. 35-45 45-60 60-75
1
(mg)
2.5 + 0.3
(mg)
5.5 + 0.3
(mg)
4.7 + 0.2
2 2. 7 + 0.2 5.5 + 0.3 4. 6 + 0.3
3 2.7 + 0.2 5.5 + 0.3 4. 7 + 0. 1
MEAN 2.6 + 0.2 5. 5 + 0.3 4.7 + 0.2
* = Significant at P<0. 05
NS = Not significant at P<£0. 05
K_ 2 3
Cer. Rep. 0.3 0 (mg) 0.40 (mg)
LSR
Part. Size 0. 2 0(mg) 0.2 0 (mg)
N for the mean = 18
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DAY (4)
D.F. M.S. P F-ratioFactors S.S.
Part. Size 0.270 2 0. 136 0.0065 13.070 *
Cer. Rep. 0. 062 6 0. 010 0.592 0. 778 NS
Error 0.600 45 0. 013
Cer. Rep. 35-45
Particle Size (um) 
45-60 60-75
(mg) (mg) (mg)
1 0. 7 + 0. 1 0. 6 + 0. 1 0. 8 + 0. 1
2 0.7 + 0.0 0.7 + 0.0 0.9 + 0. 1
3 0. 7 + 0. 1 0. 8 + 0. 1 0o 8 + 0. 1
MEAN 0.7 + 0. 1 0. 7 + 0. 1 0.8 + 0. 1
* = Significant at P<0. 05 
NS = Not significant at P<0. 05
K
Cer. Rep.
LSR
2 3
0.10 (mg) 0.20 (mg)
Part. Size 0. 06 (mg) 0. 09 (mg)
N for the mean = 18
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DAY (5)
F actors S.S. D.F. M.S. P F-ratio
Part. Size 0. 040 2 0.020 0. 064 4.500 NS
Cer. Rep. 0.027 6 0. 004 0. 843 0.448 NS
Error 0.447 45 0. 010
Particle Size (nm)
Cer. Rep. 35-45 45-60 60-75
(mg) (mg) (mg)
1 0.7 + 0.0 0.7 + 0. 1 0. 7 + 0.0
2 0.7 + 0. 1 0. 7 + 0. 1 0. 8 + 0. 1
3 0.7 + 0.2 0.7 + 0. 1 0.8 + 0,1
MEAN 0. 7 + 0. 1 0.7 + 0. 1 0.7 + 0. 1
* = Significant at P<0. 05 
NS = Not significant at P<0. 05
K
Cer.Rep. 0. 10(mg) 0.20 (mg)
LSR
Part. Size 0. 06 (mg) 0. 08 (mg)
N for the mean =18
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DAY (6)
Factors S.S. D.F. M.S. P F-ratio
Parto Size 0. 085 2 0. 042 0. 026 7. 125 *
Cer. Rep. 0. 036 6 0.006 0. 919 0.328 NS
Error 0. 813 45 0. 018
Cer. Rep. 35--45
Particle Size (um) 
45-60 60-75
1
(mg)
0.7 + 0.2
(mg)
0.7 + 0.2
(mg)
0.8 + 0. 1
2 0.7 + 0.2 0.7 + 0.2 0. 8 + 0. 1
3 0. 7 + 0o2 0.7 + 0. 1 0.8 + 0. 1
MEAN 0.7 + 0.2 0.7 + 0. 1 0. 8 + 0. 1
* = Significant at P<0. 05
NS = Not significant at P<0.05
K 2 3
Cer. Rep. 0.20 (mg) 0.20 (mg)
>
LSR
Part . Size 0. 09 (mg) 0. 1 (mg)
N for the mean =18
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DAY (7)
F actors S.S. D.F. M.S. P F-ratio
Part. Size 0. 028 2 0. 014 0. 086 3.800 NS
Cer. Rep. 0.022 6 0. 004 0. 881 0.391 NS
Error 0.427 45 0.010
Cer. Rep. 35-45
Particle
45.
Size (um) 
-60 60-75
1
(mg)
0.7 + 0.2
(mg)
0.7 + 0. 1
(mg)
0.7 + 0. 1
2 0.7 + 0. 1 0.7 + 0. 1 0.7 + 0. 1
3 0.7 + 0.1
MEAN 0.7 + 0. 1
+ - Significant at P<0. 05 
NS = Not significant at P<0. 05
K
0.7 + 0. 1
0.7 + 0. 1
0. 7 + 0. 1
0.7 + 0. 1
Cer. Rep. 0. 10 (mg) 0.20 (mg)
LSR
Part. Size 0. 06 (mg) o. 08 (mg)
N for the mean = 18
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Analysis of variance tables for determination of significant differences 
(at P<0.05) among: Days, Ceramic Replicates, and Interaction between 
Days and Ceramic Replicates during the Delivery of Gamma Globulin (mg) 
by ALCAP ceramics in a continuous flow-through system of phosphate 
buffered saline (pH 7.4) at 37°C.
Particle Size 35-45 um
F actors S.S. D.F. M.S. P. F-ratio
Days 10136. 000 6 1689.330 0. 73 x 10"24 36742.6 *
Cer. Rep. 0. 005 2 0. 003 0.932 0. 071 NS
Cer. Rep.
x Days 0. 552 12 0. 046 0.217 1.321 NS
Error 3. 653 105 0.35
Particle Size 45-60 um
F actors S.S. D.F. M.S. P. F-ratio
Days 10680.500 6 1780.090 0. 348 x 10”27 131424 *
Cer. Rep. 0. 012 2 0. 006 0. 850 0. 164 NS
Cer. Rep.
x Days 0. 163 12 0. 014 0. 970 0. 373 NS
Error 3.815 105 0. 036
Particle Size 60-75 um •
F actors S.S. D. F. M. S. P. F-ratio
Days 11918.200 6 1986.400 0.14 x IO"25 70902.5 *
Cer. Rep. 0. 101 2 0. 050 0. 192 1. 676 NS
Cer. Rep.
x Days 0.336 12 0. 028 0. 516 0. 934 NS
Error 3. 148 105 0. 030
S.S. = Sum of squares * = Significant at P<0. 05
D.F. = Degrees of freedom NS = Not significant at P<0.05 
M.S. = Mean of squares
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Appendix 3-C
Comparison among Means by Student-Newman Keuls Test on 
Amount of Chymotrypsinogen (mg) Delivered by the Different 
Particle size of ALCAP ceramics in continuous Flow-Through 
System of Phosphate Buffered Saline (pH 7.4) at 37°C on each 
day for a period of seven days.
DAYS MEANS OF AMOUNT DELIVERED
1 25.6s 26. 8m 28.7l
2 12.4l 13.4m 13.5s
3 2. 6 s 4. 7L 5.5m
4 0.7s 0. 7m 0. 8L
5 0. 7 s 0. 7m 0.7l
6 0,7s 0. 7m 0. 8l
7 0.7s 0. 7m 0. 7l
s = Particle size 35-45 um 
m = Particle size 45-60 um 
L = Particle size 60-75 um
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APPENDIX (4)
A
Analysis of variance tables for determination of significant differences
(at FKO. 05) among particle sizes and ceramic replicates during the
delivery course of insulin (mg) by ALCAP ceramics in a continuous 
flow-through system of phosphate buffered saline (pH 7.4) at 37°C for
a period of seven days.
Abbreviation Key
S.S. = Sum of squares
D.F. = Degrees of freedom
M. S. = Mean of Squares
Cer. Rep. = Ceramic capsule replicates
Part. Size = Ceramic particle size (Mm)
LSR = Least significant range.
K = The number of items over which the range is computed.
N = Number of data point used to determine the calculated value.
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DAY (1)
ANOVA
Factors S.S. D.F. M.S. P. F
Part. Size 57. 231 2 28. 625 0.255 x 10"5 216.724 *
Cer. Rep. 0. 792 6 0. 132 0. 127 1.770 NS
Error 3. 357 45 0. 075
Cer. Rep. Particle Sizes (um)
35-45
(mg)
45-60
(mg)
60-75
(mg)
1 3. 5 + 0.3 3.3 + 0.2 5. 7 + 0.3
2 3. 6 + 0.2 3.5 + 0.3 5.7 + 0. 1
3 3.3 + 0.4 3.7 + 0.3 5.6 + 0.4
Mean 3.5 4- 0.3 3.5 + 0.3 5. 6 + 0.3
* = Significant at P<0. 05 
NS = Not significant at P<0. 05
K 2 3
Cer. Rep. 0. 3 (mg)
LSR
Part. Size 0.2 (mg)
0.4 (mg)
0.2 (mg)
N for the Mean = 18
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DAY (2)
P. FF actors S.S. D.F. M.S.
Part. Size 11.383 2 5.691 0. 508 x 10"4 78.002 *
Cer. Rep. 0.438 6 0. 073 0. 394 1. 071 NS
Error 3. 065 .45 0. 068
Cer. Rep. Particle Sizes fum)
35 -45 45 -60 60-75
(nag) (nag) (nag)
1 5.5 + 0.3 5.5 + 0.3 6.3 + 0.2
2 5.3 + 0.3 5.5 + 0. 3 6. 5 + 0.3
3 5.5 + 0. 0 5. 6 + 0.2 6.5 + 0.3
Mean 5.4 + 0.3 5. 5 + 0.3 6.4 + 0.3
* = Significant at P<0.05 
NS = Not significant at P<0. 05
K 2 3
Cer. Rep. 0.3 (mg) 0.4 (mg)
LSR
Part. Size 0.2 (mg) 0.2 (mg)
N for the Mean = 18
DAY (3)
ANOVA
no
F actors
Part. Size
S.S. D. F. M.S. P. F
85.788 2 42.894 0.574 x io’6 358.003 *
Cer. Rep. 0.719 6 0. 120 0. 058 2.223 NS
Error 2.425 45 0. 054
Cer. Rep. Particle Sizes (um)
35-45 45 -60 60 -75
(mg) (mg) (mg)
1 6. 5 + 0.4 7.6 + 0.3 9.6 + 0. 1
2 6.6 + 0. 1 7.5 + 0. 1 9.3 + 0.2
3 6.4 + 0.2 7.6 + 0.3 9.7 + 0. 3
Mean 6.5 + 0.3 7. 6 + 0. 3 9.5 + 0.7
* = Significant at P<0. 05
NS = Not significant at P<0. 05
K 2 3
Cer. Rep. 0.3 (mg) 0.3 (mg)
LSR
Part. Size 0.2 (mg) 0.2 (mg)
N for the mean = 18
DAY (4)
Ill
Factors S.S. D.F. M.S. P. F
Part. Size 15.303 2 7.651 0.252 x 10“3 *
Cer. Rep. 1. 031 6 0. 172 0. 030
Error 2.972 45 0. 066
Cer. Rep.
35 -45
Particle
45
Sizes (um)
-60 60 -75
1
(mg)
8.4 + 0.3
(mg) (mg)
8.2 + 0.3 9.3 + 0.1
2 8. 5 + 0.3 8.4 + 0.2 9.6 + 0.4
3 8.5 + 0.2 8.6 + 0.2 9.8 + 0.2
Mean 8.5 + 0.3 8.4 + 0.3 9.6 + 0.7
* = Significant at P<0.05 
NS - Not significant at P<0.05
K 2 3
Cer. Rep.
LSR
Part. Size
0.3 (mg) 0.4 (mg)
0.2 (mg) 0.2 (mg)
N for the mean = 18
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DAY (5)
ANOVA
Factors S.S. D.F. M.S. P. F
Part. Size 11.445 2 5.722 0.258 x 10"3 44.144 *
Cer. Rep. 0. 778 6 0. 130 0. 054 2.268 NS
Error 2.572 45 0.057
Cer. Rep. Particle Sizes (um)
35-45 45 -60 60-75
(mg) (mg) (mg)
1 8.2 + 0.2 8.2 + 0.2 7.5 + 0.1
3 8. 5 + 0.3 8.3 + 0. 1 7. 3 + 0.3
8.7 + 0.3 8.3 + 0.3 7.4 + 0.3
Mean 8. 5 + 0.3 8. 3 + 0.2 7.4 + 0.2
* = Significant at P<0. 05 
NS - Not significant at P^O. 05
K 2
Cer. Rep. 0. 3 (mg)
LSR
Part. Size 0.2 (mg)
3
0.3 (mg)
0. 2 (mg)
N for the mean = 18
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DAY (6)
F actors S. S. DCF. M.S. P. F
Part. Size 11. 967 2 5.984 0.221x 10‘2 20.032 *
Cer. Rep. 1.792 6 0.299 0.237 x 10"2 4.082 *
Error 3.293 45 0. 073
Cer. Rep.
35-45
Particle Sizes (um) 
45-60 60-75
(mg) (mg) (mg)
1 6.7 + 0.3 5.6 + 0.3 6.5 + 0. 1
2 6.6 + 0.3 5. 7 + 0.3 6.7 + 0.3
3 6. 1 + 0. 1 5.3 + 0.3 6.4 + 0.3
Mean 6.5 +_ 0.4 5.5 +^0.3 6. 5 Jr 0.3
* = Significant at P<0.05
NS = Not significant at P<,0. 05
K 2 3
Cer.Rep. 0.3 (mg) 0.4 (mg)
LSR
Part.Size 0.2 (mg) 0.2 (mg)
N for the mean =18
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DAY (7)
ANOVA
D.F. M.S. P. FFactors S.S.
Part. Size 14.303 2 7. 151 0.879 x 10"4 64.469 *
Cer. Rep. 0. 666 6 0. Ill 0.311 1.225 NS
Error 4. 073 45 0. 091
Cer. Rep.
35 -45
Particle
45
Sizes (urn) 
-60 60-75
1
(mg)
5.6 4 0.4
(mg)
5.4 + 0.2
(mg)
4.5 + 0. 1
2 5.3 + 0.3 5.4 + 0. 3 4. 5 + 0.4
3 5.7 + 0.2 5.5 + 0. 3 4.2 + 0.3
Mean 5. 5 + 0.3 6. 5 + 0.4 4.4 + 0. 3
* = Significant at P<0. 05
NS = Not significant at P<0. 05
K 2 3
Cer. Rep. 0.4 (mg) 0.4 (mg)
LSR
Part. Size 0.2 (mg) 0.3 (mg)
N for the mean = 18
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Analysis of variance tables for determination of significant differences 
(at P<0. 05) among: Days, Ceramic Replicates, and Interaction between 
Days and Ceramic Replicates during the Delivery of Gamma Globulin (mg) 
by ALCAP ceramics in a continuous flow-through system of phosphate 
buffered saline (pH 7,4) at 37°C.
Particle Size 35-45 um
F actors S.S. D.F. M. S. P. F-ratio
Days 341.231 6 56.872 0.16 x 10"10 216.961 *
Cer. Rep. 0. 048 2 0. 024 0. 732 0.313 NS
Days x
Cer. Rep. 3. 146 12 0. 262 0.28 x 10”3 3.439 *
Error 8. 003 105 0. 076
Particle Size 45-60 um
F actors S.S. D.F. M. S. P. F-ratio
Days 355.665 6 59. 278 0. 16 x 10"13 689.125 *
Cer. Rep. 0.310 2 0. 155 0. 078 2.619 NS
Days x
Cer. Rep. 1. 032 12 0. 086 0. 154 1.453 NS
Error 6.215 102 0. 059
Particle Size 60-75 um
F actors S.S. D.F. M. S. P. F-ratio
Days 401.098 6 66. 850 0.2 xlO”12 451.603 *
Cer. Rep. 0. 026 2 0. 013 0. 829 0. 188 NS
Days x
Cer. Rep. 1. 776 12 0. 148 0. 010 2. 149 *
Error 7.232 105 0. 069
S. S. = Sum 
D.F. = Deg
of squares 
rees of freedom
* = Significant at P<0. 05
NS = Not significant at P<0. 05
M. S. = Mean of squares
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Appendix 4-C
Comparison Among Means by Student-Newman Keuls Test on 
Amount of Insulin (mg) Delivered by the Different Particle Sizes of 
ALCAP Ceramics in Continuous Flow-Through System of Phosphate 
Buffered Saline (pH 7.4) at 37°C on each day for a period of seven days
DAYS
1
MEANS OF AMOUNT DELIVERED
3. 5s 3. 5m 5.6L
2 5.4s 5. 5m 6.4L
3 6.5s 7.6m 9.5L
4 8.4m 8. 5s 9.6L
5 7.4L 8. 3m 8. 5s
6 5.5m 6. 5s 6.5L
7 4.4L 5. 5s 6.5m
s = Particle size 35-45 um 
m = Particle size 45-60 um 
L = Particle size 60-75 um
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APPENDIX 5
Preparation of Phosphate Buffer Saline (pH 7.4)
For 15 Liters
1. Dissolve 122. 6 grams NaC 1 in about 500 ml distilled water in a 
1000 ml beaker.
2. Add 85.7 ml, .5 MNaH2PC>4.H20 (sodium phosphate-monobasic).
3. Add 222. 9 ml, of . 5 M NA2HPO4 (sodium phosphate-dibasic).
4. Add 0. 1 g of Merthulate to prevent contamination.
5. Dissolve completely and transfer to 15 liter contained. Dilute to 
15 liters with distilled water.
6. Check pH.
7. Store in refrigerator.
8. Adjust pH to using the monobasic solution if it is above 7.4 or the 
diabasic solution if it is below 7.4.
Scanning Electron Microscopy (Method of Khot, et al. , 1980)
A JEOL JSM-U3 scanning electron microscope (SEM) with a 
resolution of 200°A was used to magnify the cracked surface of the 
ceramic 250 X. A conductive coating of a 60% Ag - 40% Pd alio was
vapor deposited on a piece of a cracked ceramic surface before they
were used to deliver the various polypeptides.
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Lowry Determination of Protein
1. Prepare the following reagents.
Reagent Ap - NA2C4H4O6* 2H2O (sodium tartrate-------- 2 grams.
Add distilled water to make 100 ml.
Reagent A2: - CuSo4» 5H2O (copper sulfate)-------- 1 gram.
Add distilled water to make 100 ml.
Reagent A3: - Na2CC>3 (sodium carbonate)-------- 20.0 grams.
Add 0. 1 N NaOH to make 1 liter.
Reagent A: -
To prepare Reagent A, mix the following quantities
together in the following sequence. Reagent A should be prepared
new for each test and not kept more than 24 hours.
A1 0. 5 ml
A2 0. 5 ml
A3 50. 0 ml
Reagent B: - Phenol reagent (Folin Ciochlteau) comes bottled in
a 2N solution for the test. Dilute this to IN.
Note: Use volumetric flasks to prepare reagents Ap A2 and A3.
Preparation of Standard Curve
Procedure:
1. To prepare protein standard solution, mix a stock solution of
Bovine Serum Albumin in distilled water at a concentration of
700 microgram/ml and use the following dilutions for standard
curve.
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Test Tube #1 #2 #3 #4 #5
Cone of BSA 
(ug/ml)
0 35 70 175 350
Water 1ml 0. 95ml 0. 9ml 0. 75ml 0. 5ml
BSA 0ml 0. 05ml 0. 1ml 0.25ml 0. 5ml
To run the assay, mix 1 ml of each BSA standard with 5. 0 ml of
Reagent A and let this mixture stand at room temperature for 10
minutes. To this, add 0.5 ml of Reagent B and immediately mix
in a vortex mixer. Allow all samples to stand at room temperature
for 30 minutes. Record optical density on a Bausch and Lomb Spec-
tronic 20 at 700 nm. Be sure to use the right lamp and the red filter.
Read the optical density of each tube and plot it in units of ug/ml of
BSA.
Preparation of Polypeptide Standards
(1) Insulin
Crystalline insulin from bovine pancreas (No. 1-5500) yielded 
hazy solution in distilled water at 10 mg/ml. Therefore, it was dissolved 
in acid medium (pH 3) as per instruction by Sigma Chemical Company.
The concentration used for conducting this research was 100 mg/ml.
(2) Gamma Globulin, BSA, and Chymotrypsinogen-A
To prepare the above polypeptide standards (100 mg/ml) dissolve 
10 mg of the polypeptide in a 100 ml of PBS using very slow magnetic 
stearer (about 20 rpm) and a sterilized beaker, for about 4 hours or 
until all the floating powder becomes suspended.
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Appendix (6)
Fabrication of Ceramics 
(Procedure of Khot, 1979)
Final shape of the ceramic was obtained by following the step by
step procedure as given below:
(1) 58 grams of Aluminum oxide, 42 grams of calcium oxide, and 20
grams of phosphorous pentoxide were weighed and placed in a
bottle. The material was then placed on a ball mill roller for
10 mins, to obtain thorough mixing.
(2) Ceramic crucibles (Norton Company) were filled with the above
mixture in a hood. The mixture was loosely filled so that the
crucibles could be used again.
(3) The furnace (Leco) was preheated at 316°C and crucibles contain­
ing the mixture were fixed at 1315°C for 10 hours. The furnace
was turned off after 10 hours and allowed to cool for 24 hours.
(4) The warm crucibles were removed from the furnace one at a time.
The calcined material was ground to a powder state using a mortar
and pestel.
(5) The ground powder was placed on a Tyler sieve stack. The follow­
ing mesh sieves were used to separate various particles. The
sieves were used to separate various particles. The sieves were
stacked on a shaker (Ro-Tap-Testing Sieve Shaker) and the contents
were shaken for 10 minutes. The sieve sizes were stacked as shown
in the table below.
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(6) Powders of various particles size ranges were stored in capped 
bottles. The bottles were labelled with particle size range and
rate of calcining.
Table:
Stack Placement Sieve Size Particle Size (u)
1 70 210
2 100 147
3 120 125
4 170 88
5 200 75
6 250 60
7 325 45
8 400 35
9 Catch Pan 35
(7) The particle size powders ranges 35-45 u, 45-60 u, and 60-75 u
were used to prepare the ceramic cylinders. 3.3 grams of each
of the above calcined-particle-size-range powders were added to
0. 1 grams of polyvinyl alcohol powder (147 u) and mixed thoroughly.
Polyvinyl alcohol acts as a binder as well as a die lubricant. This
mixture was put into a cylindrical tungeston die (2.0 cm long, 1.3
cm outside diameter and 0. 5 cm inside diameter) and pressed hy­
draulically in a Clifton Hydraulic Press for five seconds at approxi­
mately 11,000 psi.
(8) The furnace was preheated at 316°C and all ceramic cylinders were 
placed into it for final sintering immediately after pressind. All
the ceramics were fired at 1425°C for 24 hours. After 24 hours
the furnace was turned off and allowed to cool for 24 hours. The
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ceramics then stored in a vacuumed dry container to be used for de­
livering gamma globulin, bovine serum albumin, chymotrypsinogen,
and insulin in a continuous flow-through system of phosphate buffered 
saline (pH 7.4) at 37°C for a period of 7 days.
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